What is KYNB's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.02B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for KYNB?

P/E (TTM) is 0.13 and 52-week range is $5.62 to $11.65 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s KYNB figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for KYNB?

The company profile lists revenue (TTM) near $5M, net income (TTM) near $102M, EPS (TTM) near $45.30 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Kyntra Bio Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Francisco, California, US, 4M shares outstanding, ISIN US31572Q8814 when available from company profile and filing metadata.

Chartloom

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Kyntra Bio, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. The company is headquartered in San Francisco, California and currently employs 34 full-time employees. The company went IPO on 2014-11-14. The firm is focused on development of novel therapies in oncology and rare disease. The firm continues to evaluate the development plan for the Phase III trial of roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase II development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. Roxadustat (EVRENZO) is approved in Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis.

Employees

Website

www.kyntrabio.com/home

IPO

2014-11-14

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)